ClinicalTrials.gg
TerminatedNCT02261233Updated Nov 12, 2026Results posted

Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach

An interventional study of Osteopathic manipulative treatment and No intervention in Low Back Pain, sponsored by Michigan State University. Terminated at 3 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Michigan State University · Not applicable, Interventional, and Basic science

How we know

Why this study was terminated
Funding for this project ended as of August 31, 2018
Updated Nov 12, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
285th of 623
95 · median 79
Started
2015
with 34 others
No phase
408 of 712
62 open now
Registered
284th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 285th largest by enrollment of the 623 interventional ones that give a count, is one of 35 that started in 2015, is one of 408 with no phase, and was the 284th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this project is to develop sensitive and objective clinical research tools for the assessment of postural control of the trunk. In order to accomplish this goal, we aim to quantify balance performance in an unstable seated task. Specifically, the investigators will quantify balance performance in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in balance performance after a single session of osteopathic manipulative treatment as well as after 4 sessions of osteopathic manipulative treatment and this improvement will be greater than any learning effect.

A secondary objective of this study is to quantify differences in patient-oriented outcome measures (e.g., self-reported pain, disability) in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in these self-reported outcomes following osteopathic manipulative treatment. The association between improvement in postural control parameters and patient-oriented measures will also be explored.

03

Conditions studied

  • Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants must meet all of the inclusion criteria to participate in the study. Below is a list of inclusion criteria for LBP participants:

  • Age 21-65 years
  • Independently ambulatory
  • Able to speak and read English
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Willing to be randomized to either immediate or delayed treatment group.
  • Musculoskeletal pain - primarily in the low back region
  • Pain rating equal to or greater than 3 out of10 as indicated on the Numeric Rating Scale for Pain
  • Disability equal to or greater than 26% as indicated on the Oswestry Disability Questionnaire

Exclusion criteria

Exclusion Criteria:

All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. Exclusion criteria will be self-reported. However, during each treatment session, the physicians will be watching for clinical signs and symptoms not consistent with physical findings that are suggestive of the presence of any of the exclusion criteria. In such a case, further treatment will be discontinued and the subject will be excluded.

Below is a list of exclusion criteria:

  • Inability or unwillingness of individual to give written .
  • Physical therapy or any other form of manual medicine (e.g., Osteopathic Manipulative Medicine, Chiropractic Manipulation, etc.), acupuncture or spinal injections within one month prior to study enrollment
  • Workers' compensation benefits in the past 3 months or ongoing medical legal issues
  • Possibly pregnant
  • Obesity (>32)
  • Currently using electrical implants (e.g., cardiac pacemakers, drug delivery pumps, etc.)

History of:

  • Spinal surgery
  • Spinal fracture
  • Spinal infection (e.g., osteomyelitis)
  • Cancer

Unresolved symptoms from:

  • Head trauma
  • Inner ear infection with associated balance and coordination problems
  • Orthostatic hypotension
  • Uncontrolled hypertension
  • Vestibular disorder (e.g. vertigo)

Current diagnosis of:

  • Significant spinal deformity (e.g., scoliosis > 20 degrees, torticollis)
  • Ankylosing spondylitis
  • Spondylolisthesis grades III or IV
  • Cauda equine syndrome
  • Rheumatoid arthritis
  • Osteoporosis
  • Angina or congestive heart failure symptoms
  • Active bleeding or infection in the back
  • Blindness
  • Seizures
  • Neurologic disease (e.g., Parkinson's disease, multiple sclerosis, cerebral palsy, Alzheimer's disease, amyotrophic lateral sclerosis, stroke or in the past year, cervical dystonia)

Conditions recognized by a physician any time during the study:

  • Significant or worsening signs of neurologic deficit
  • Symptoms are not consistent with mechanical findings
  • Other conditions impeding protocol implementation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    OMT first, then No intervention

    This arm received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week), then received no intervention after for approximately 4 weeks.

    Procedure: Osteopathic manipulative treatment · Other: No intervention

  • Experimental
    No intervention, then OMT

    This arm received no intervention after for approximately 4 weeks, then received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week).

    Procedure: Osteopathic manipulative treatment · Other: No intervention

Interventions

  • ProcedureOsteopathic manipulative treatment

    Up to 4 sessions of osteopathic manipulative treatment (once per week)

  • OtherNo intervention

    No interventions for approximately 4 weeks

06

What researchers measure

Primary outcomes

  1. Postural Control

    Postural control will be assessed in an unstable seated task, in which subjects will be asked to balance on a specially designed seat that wobbles side to side. Participant will be asked to maintain their upright posture while keeping their eyes open. The root mean square error (difference between the trunk angle from their upright position) is computed then converted to Z-score based the study populations' baseline mean and standard deviation. The score ranged from -1.67 to 2.95. Z-score of 0 indicates study population's average at the baseline. Higher Z-score indicates worse performance.

    Time frame: Baseline, Week 1, Week 4 (crossover), & Week 8

  2. Trunk Muscle Reflex Latency

    Subjects will be pulling with their trunk on a cable held by an electromagnet. The electromagnet will be suddenly released. Trunk muscle response to sudden load release will be measured on electromyographical recordings.

    Time frame: Baseline, Week 1, Week 4 (crossover), & Week 8

Secondary outcomes

  1. Patient Reported Outcomes Measurement Information System (PROMIS)

    Assesses changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire. Patients rated the statements in each domain from 0-5. Scores are summed for each domain (ranges from 4 to 20), and converted to T-scores using PROMIS conversion table (for details see http://www.healthmeasures.net/promis-scoring-manuals) . T-score of 50 indicates population average with a standard deviation of 10. Higher scores indicate worse outcomes for pain interference, sleep disturbance, fatigue, depression, and anxiety; whereas higher scores indicate better outcomes for physical function and Satisfaction with participation in social roles.

    Time frame: Baseline and Week 4 (crossover point)

  2. Concomitant Medication

    Assesses the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.

    Time frame: Baseline, Week 4 (crossover), Week8

  3. Oswestry Disability Index

    Assesses changes in functional activities related to low back disability with the Oswestry Disability Index questionnaire. Patients selected statements that best described their condition from 10 domains affecting daily life. Each domain is scored from 0 (no disability) to 5 (highest disability). Scores from each domains are summed then percentages are calculated out of 50. Higher percentage is associated with higher disability.

    Time frame: Baseline, Week 4 (crossover), and Week 8

  4. Fear Avoidance Beliefs Questionnaire

    The Fear Avoidance Beliefs questionnaire (FABQ) assesses effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).

    Time frame: Baseline, Week 4 (crossover), and Week 8

07

Results

Posted Nov 12, 2026

Participant flow

Participants were recruited from general population in the Greater Lansing area between May 2015 to June 2018.

Participant flow — Overall Study
MilestoneOMT First, Then No InterventionNo Intervention, Then OMT
Started4040
Visit 1 - patient reported outcome (baseline)4040
Visit 1 - biomechanical testing (baseline)4039
Visit 2 - patient reported outcome3536
Visit 2 - biomechanical testing3434
Visit 3 - patient reported outcome (crossover)3133
Visit 3 - biomechanical testing (crossover)3133
Visit 4 - patient reported outcome3033
Visit 4 - biomechanical testing3033
Completed3033
Not completed107
Withdrew: Lost to follow-up23
Withdrew: Withdrawal by subject84

Outcome measures

PrimaryPostural Control

Postural control will be assessed in an unstable seated task, in which subjects will be asked to balance on a specially designed seat that wobbles side to side. Participant will be asked to maintain their upright posture while keeping their eyes open. The root mean square error (difference between the trunk angle from their upright position) is computed then converted to Z-score based the study populations' baseline mean and standard deviation. The score ranged from -1.67 to 2.95. Z-score of 0 indicates study population's average at the baseline. Higher Z-score indicates worse performance.

Time frame:
Baseline, Week 1, Week 4 (crossover), & Week 8
Reported as:
Mean · Z-score
Postural Control
Z-scoreOMT First, Then No InterventionNo Intervention, Then OMT
Baseline - Eyes Open Root mean square error (RMSE)-0.07 ± 0.930.09 ± 1.11
Week 1- Eyes Open RMSE0.01 ± 0.990.04 ± 0.84
Week 4- Eyes Open RMSE0.10 ± 0.94-0.13 ± 0.90
Week 8 - Eyes Open RMSE-0.10 ± 0.95-0.04 ± 0.99
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.55 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.035 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
PrimaryTrunk Muscle Reflex Latency

Subjects will be pulling with their trunk on a cable held by an electromagnet. The electromagnet will be suddenly released. Trunk muscle response to sudden load release will be measured on electromyographical recordings.

Time frame:
Baseline, Week 1, Week 4 (crossover), & Week 8
Reported as:
Mean · millisecond
Trunk Muscle Reflex Latency
millisecondOMT First, Then No InterventionNo Intervention, Then OMT
Baseline- Back muscle shut-off latency106.26 ± 59.75103.04 ± 63.88
Week 1- Back muscle shut-off latency101.63 ± 61.8973.62 ± 49.13
Week 4 - Back muscle shut-off latency106.97 ± 63.3491.00 ± 51.73
Week 8 - Back muscle shut-off latency125.12 ± 55.4791.08 ± 46.44
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.08 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.34 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
SecondaryPatient Reported Outcomes Measurement Information System (PROMIS)

Assesses changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire. Patients rated the statements in each domain from 0-5. Scores are summed for each domain (ranges from 4 to 20), and converted to T-scores using PROMIS conversion table (for details see http://www.healthmeasures.net/promis-scoring-manuals) . T-score of 50 indicates population average with a standard deviation of 10. Higher scores indicate worse outcomes for pain interference, sleep disturbance, fatigue, depression, and anxiety; whereas higher scores indicate better outcomes for physical function and Satisfaction with participation in social roles.

Time frame:
Baseline and Week 4 (crossover point)
Reported as:
Mean · T-score
Patient Reported Outcomes Measurement Information System (PROMIS)
T-scoreOMT First, Then No InterventionNo Intervention, Then OMT
Baseline - Pain interference62.86 ± 5.0360.36 ± 5.21
Week 4 - Pain interference62.13 ± 6.9158.51 ± 5.99
Baseline - Satisfaction with participation in social roles42.35 ± 6.3746.45 ± 5.51
Week 4 - Satisfaction with participation in social roles42.09 ± 7.4143.01 ± 7.59
Baseline - Sleep disturbance56.75 ± 9.1352.92 ± 6.64
Week 4 - Sleep disturbance53.81 ± 8.8653.80 ± 7.95
Baseline - Fatigue56.39 ± 9.6654.26 ± 8.18
Week 4 - Fatigue55.91 ± 10.7355.47 ± 9.58
Baseline - Depression48.57 ± 7.8349.13 ± 7.84
Week 4 - Depression45.91 ± 7.0348.71 ± 9.08
Baseline - Anxiety53.81 ± 8.3849.68 ± 8.44
Week 4 - Anxiety47.37 ± 7.9949.60 ± 8.94
Baseline - Physical function39.74 ± 4.2943.21 ± 6.73
Week 4 - Physical function40.03 ± 5.1242.08 ± 5.89
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.31 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.07 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.03 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.43 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.10 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.0001 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.71 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
SecondaryConcomitant Medication

Assesses the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.

Time frame:
Baseline, Week 4 (crossover), Week8
Reported as:
Mean · Number of medication
Concomitant Medication
Number of medicationOMT First, Then No InterventionNo Intervention, Then OMT
Baseline2.8 ± 4.82.6 ± 3.8
Week 42.1 ± 4.92.5 ± 4.1
Week 82.4 ± 5.01.9 ± 2.4
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.2869 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
SecondaryOswestry Disability Index

Assesses changes in functional activities related to low back disability with the Oswestry Disability Index questionnaire. Patients selected statements that best described their condition from 10 domains affecting daily life. Each domain is scored from 0 (no disability) to 5 (highest disability). Scores from each domains are summed then percentages are calculated out of 50. Higher percentage is associated with higher disability.

Time frame:
Baseline, Week 4 (crossover), and Week 8
Reported as:
Mean · % (out of 50)
Oswestry Disability Index
% (out of 50)OMT First, Then No InterventionNo Intervention, Then OMT
Baseline34.8 ± 12.029.6 ± 10.3
Week 431.9 ± 12.029.1 ± 13.4
Week 829.4 ± 13.228.0 ± 12.3
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.21 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
SecondaryFear Avoidance Beliefs Questionnaire

The Fear Avoidance Beliefs questionnaire (FABQ) assesses effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).

Time frame:
Baseline, Week 4 (crossover), and Week 8
Reported as:
Mean · scores on a scale
Fear Avoidance Beliefs Questionnaire
scores on a scaleOMT First, Then No InterventionNo Intervention, Then OMT
Baseline - FABQ-Work15.8 ± 10.111.8 ± 9.3
Week 4 - FABQ-Work13.6 ± 11.011.2 ± 8.8
Baseline - FABQ-Physical Activity14.7 ± 5.012.9 ± 5.2
Week 4 - FABQ-Physical Activity15.5 ± 4.212.5 ± 5.2
Week 8 - FABQ-Work15.3 ± 11.211.7 ± 9.6
Week 8 - FABQ-Physical Activity15.0 ± 4.212.2 ± 6.1
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.81 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)
  • OMT First, Then No Intervention vs No Intervention, Then OMT · Mixed Models Analysis · p = 0.08 (FABQ-Work and PROMIS physical function at baseline were added as covariates, along with the baseline value for the outcome measure.)

Adverse events

Collected over Baseline - Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osteopathic Manipulative Treatment (OMT)0/73 (0%)0/73 (0%)39/73 (53.4%)
No Intervention0/71 (0%)1/71 (1.4%)15/71 (21.1%)
Most frequent serious events
Most frequent serious events
EventOsteopathic Manipulative Treatment (OMT)No Intervention
ColitisGastrointestinal disorders0/731/71
Most frequent other events
Most frequent other events
EventOsteopathic Manipulative Treatment (OMT)No Intervention
Back painMusculoskeletal and connective tissue disorders26/739/71
MyalgiaMusculoskeletal and connective tissue disorders18/732/71
ArthralgiaMusculoskeletal and connective tissue disorders7/733/71
Muscle fatigueMusculoskeletal and connective tissue disorders5/733/71

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OMT First, Then No InterventionNo Intervention, Then OMTTotal
<=18 years000
Between 18 and 65 years394079
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)OMT First, Then No InterventionNo Intervention, Then OMTTotal
Female242549
Male161531
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OMT First, Then No InterventionNo Intervention, Then OMTTotal
American Indian or Alaska Native101
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American426
White263359
More than one race415
Unknown or Not Reported336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OMT First, Then No InterventionNo Intervention, Then OMTTotal
Hispanic or Latino213
Not Hispanic or Latino353772
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)OMT First, Then No InterventionNo Intervention, Then OMTTotal
United States404080
Average Pain
Average Pain(units on a scale)OMT First, Then No InterventionNo Intervention, Then OMTTotal
Mean5.98 ± 1.755.80 ± 1.835.89 ± 1.78
Oswestry Disability Index (OSW)
Oswestry Disability Index (OSW)(%)OMT First, Then No InterventionNo Intervention, Then OMTTotal
Mean35.3 ± 11.830.7 ± 10.633.0 ± 11.4
Fear Avoidance Belief Questionnaire (FABQ)
Fear Avoidance Belief Questionnaire (FABQ)(units on a scale)OMT First, Then No InterventionNo Intervention, Then OMTTotal
Work (out of 42)17.33 ± 10.4611.80 ± 8.6814.56 ± 9.95
Physical Activity (out of 24)14.75 ± 4.8613.00 ± 5.2513.88 ± 5.1

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • MSU Osteopathic Manipulative Medicine
    East Lansing, Michigan 48823, United States
  • MSU Musculoskeletal Rehabilitation
    Lansing, Michigan 48891, United States
  • Michigan State University Center for Orthopedic Research
    Lansing, Michigan 48910, United States
09

References and documents

Publications

  • Radebold A, Cholewicki J, Polzhofer GK, Greene HS. Impaired postural control of the lumbar spine is associated with delayed muscle response times in patients with chronic idiopathic low back pain. Spine (Phila Pa 1976). 2001 Apr 1;26(7):724-30. doi: 10.1097/00007632-200104010-00004. PubMed 11295888 ↗
  • Ramadan A, Cholewicki J, Radcliffe CJ, Popovich JM Jr, Reeves NP, Choi J. Reliability of assessing postural control during seated balancing using a physical human-robot interaction. J Biomech. 2017 Nov 7;64:198-205. doi: 10.1016/j.jbiomech.2017.09.036. Epub 2017 Oct 7. PubMed 29066244 ↗
  • Reeves NP, Sal Y Rosas Celi VG, Ramadan A, Popovich JM Jr, Prokop LL, Zatkin MA, DeStefano LA, Francisco TJ, Rowan JJ, Radcliffe CJ, Choi J, Cowdin ND, Cholewicki J. Stability threshold during seated balancing is sensitive to low back pain and safe to assess. J Biomech. 2021 Aug 26;125:110541. doi: 10.1016/j.jbiomech.2021.110541. Epub 2021 Jun 7. PubMed 34198020 ↗
  • Cholewicki J, Pathak PK, Reeves NP, Popovich JM Jr. Model Simulations Challenge Reductionist Research Approaches to Studying Chronic Low Back Pain. J Orthop Sports Phys Ther. 2019 Jun;49(6):477-481. doi: 10.2519/jospt.2019.8791. Epub 2019 May 15. PubMed 31092125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2015 to primary completion in Aug 2018, 38 months.

Results were first posted in Nov 2026, 8 years 2 months after primary completion.

Start moved once since we started tracking on Sep 25, 2026: Apr 2014 → Jun 2015, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2014
First posted
Oct 10, 2014
StartActual
Jun 5, 2015was Apr 2014
Primary completionActual
Aug 31, 2018
CompletionActual
Aug 31, 2018
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Start date
Apr 1, 2014→Jun 5, 2015
Nov 12, 2026
Enrollment
63→95
Nov 12, 2026
Interventions
Added No intervention. Arms added: OMT first, then No intervention·No intervention, then OMT; arms removed: Immediate treatment·Delayed treatment
Nov 12, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in postural controlPostural ControlTime frame: Change from baseline to shortly after first treatment (1-2 days), from baseline to an expected average of week 4, and from week 4 to an expected average of week 8. → Baseline, Week 1, Week 4 (crossover), & Week 8
  • EditedChange in trunk muscle reflex latencyTrunk Muscle Reflex LatencyTime frame: Change from baseline to shortly after first treatment (1-2 days), from baseline to an expected average of week 4, and from week 4 to an expected average of week 8. → Baseline, Week 1, Week 4 (crossover), & Week 8
Nov 12, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedChange in Patient Reported Outcomes Measurement Information System (PROMIS)Time frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline and Week 4 (crossover point)
  • EditedChange in concomitant medicationConcomitant MedicationTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks).tcome measure until the end, an expected average of 8 weeks. → Baseline, Week 4 (crossover), Week8
  • EditedChange in Oswestry Disability IndexTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4 (crossover), and Week 8
  • ChangedBefore Change in fear avoidance behaviorNow Fear Avoidance Beliefs QuestionnaireTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4 (crossover), and Week 8
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Start date Apr 1, 2014→Jun 5, 2015
    Enrollment 63→95
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in postural controlPostural ControlTime frame: Change from baseline to shortly after first treatment (1-2 days), from baseline to an expected average of week 4, and from week 4 to an expected average of week 8. → Baseline, Week 1, Week 4 (crossover), & Week 8
    • EditedChange in trunk muscle reflex latencyTrunk Muscle Reflex LatencyTime frame: Change from baseline to shortly after first treatment (1-2 days), from baseline to an expected average of week 4, and from week 4 to an expected average of week 8. → Baseline, Week 1, Week 4 (crossover), & Week 8
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedChange in Patient Reported Outcomes Measurement Information System (PROMIS)Time frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline and Week 4 (crossover point)
    • EditedChange in concomitant medicationConcomitant MedicationTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks).tcome measure until the end, an expected average of 8 weeks. → Baseline, Week 4 (crossover), Week8
    • EditedChange in Oswestry Disability IndexTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4 (crossover), and Week 8
    • ChangedBefore Change in fear avoidance behaviorNow Fear Avoidance Beliefs QuestionnaireTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4 (crossover), and Week 8
    Interventions Added No intervention. Arms added: OMT first, then No intervention·No intervention, then OMT; arms removed: Immediate treatment·Delayed treatment
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02261233
Responsible party
Jacek Cholewicki (Walter F. Patenge Professor, Michigan State University) — Principal investigator
First posted
Oct 10, 2014
Start date
Jun 5, 2015
Primary completion
Aug 31, 2018
Completion
Aug 31, 2018
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Jacek Cholewicki, PhD
principal investigator · Michigan State University
Norman P Reeves, PhD
principal investigator · Michigan State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion